VIA
CRL icon

Vident Investment Advisory’s Charles River Laboratories CRL Stock Holding History

Vident Investment Advisory’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,071
Closed -$216K – 1223
2023
Q1 		$216K Buy
+1,071
New +$243K 0.01% 1080
2022
Q2 		– Sell
-4,268
Closed -$1.21M – 1298
2022
Q1 		$1.21M Buy
+4,268
New +$1.32M 0.03% 622

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Vident Investment Advisory's CRL Position: Q2 2023 in Review

Vident Investment Advisory sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 1,071 shares — an estimated $216K sold.

Vident Investment Advisory first reported a position in CRL in Q1 2022 and held it in 2 quarters. The position peaked at $1.21M in Q1 2022. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Vident Investment Advisory reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 1,071 Charles River Laboratories shares in Q2 2023, an estimated $216K.
  • Vident Investment Advisory first reported a position in Charles River Laboratories in Q1 2022 and held it in 2 quarters.
  • Vident Investment Advisory's Charles River Laboratories position peaked at $1.21M in Q1 2022.
  • 612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.